- Home
- ADGM vs ABVC Comparison
ADGM vs ABVC Comparison
Compare ADGM & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADGM
- ABVC
- Stock Information
- Founded
- ADGM 2011
- ABVC 2015
- Country
- ADGM United States
- ABVC United States
- Employees
- ADGM N/A
- ABVC N/A
- Industry
- ADGM
- ABVC Biotechnology: Pharmaceutical Preparations
- Sector
- ADGM
- ABVC Health Care
- Exchange
- ADGM NYSE
- ABVC Nasdaq
- Market Cap
- ADGM 19.7M
- ABVC 18.8M
- IPO Year
- ADGM N/A
- ABVC N/A
- Fundamental
- Price
- ADGM $1.22
- ABVC $1.46
- Analyst Decision
- ADGM
- ABVC
- Analyst Count
- ADGM 0
- ABVC 0
- Target Price
- ADGM N/A
- ABVC N/A
- AVG Volume (30 Days)
- ADGM 6.1M
- ABVC 248.3K
- Earning Date
- ADGM 05-23-2025
- ABVC 04-30-2025
- Dividend Yield
- ADGM N/A
- ABVC N/A
- EPS Growth
- ADGM N/A
- ABVC N/A
- EPS
- ADGM N/A
- ABVC N/A
- Revenue
- ADGM $602,000.00
- ABVC $508,383.00
- Revenue This Year
- ADGM N/A
- ABVC $735.18
- Revenue Next Year
- ADGM N/A
- ABVC N/A
- P/E Ratio
- ADGM N/A
- ABVC N/A
- Revenue Growth
- ADGM 100.67
- ABVC 1904.43
- 52 Week Low
- ADGM $0.63
- ABVC $0.40
- 52 Week High
- ADGM $9.34
- ABVC $1.40
- Technical
- Relative Strength Index (RSI)
- ADGM N/A
- ABVC 64.11
- Support Level
- ADGM N/A
- ABVC $1.18
- Resistance Level
- ADGM N/A
- ABVC $1.36
- Average True Range (ATR)
- ADGM 0.00
- ABVC 0.14
- MACD
- ADGM 0.00
- ABVC 0.05
- Stochastic Oscillator
- ADGM 0.00
- ABVC 63.74
About ADGM ADAGIO MEDICAL HOLDINGS INC
Adagio Medical Holdings Inc is an innovator in catheter ablation technologies for the treatment of cardiac arrhythmias. The company focuses on developing cryoablation technologies that create contiguous, transmural lesions to treat cardiac arrhythmias, including paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.